APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Medications for Alcohol Use Disorder (AUD)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Medications for Alcohol Use Disorder (AUD) Market Outlook and Growth Opportunities 2026

Report ID 174011310427 December 2025199 pages

Choose your research edition.

Industry ResearchMedications for Alcohol Use Disorder (AUD) Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Medications for Alcohol Use Disorder (AUD) Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Medications for Alcohol Use Disorder (AUD) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Medications for Alcohol Use Disorder (AUD) Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Medications for Alcohol Use Disorder (AUD) Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Medications for Alcohol Use Disorder (AUD) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Medications for Alcohol Use Disorder (AUD) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Medications for Alcohol Use Disorder (AUD) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Medications for Alcohol Use Disorder (AUD) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Medications for Alcohol Use Disorder (AUD) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Medications for Alcohol Use Disorder (AUD) market include Teva, Sun Pharmaceutical Industries, Merck KGaA, Mylan, Beijing Wellso Pharmaceutical Co, Zydus Pharmaceuticals, Taj Pharmaceuticals, TAGI Pharma Inc. and Rusan Pharma Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Medications for Alcohol Use Disorder (AUD) market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Medications for Alcohol Use Disorder (AUD) and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Medications for Alcohol Use Disorder (AUD) revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Medications for Alcohol Use Disorder (AUD) market.

Medications for Alcohol Use Disorder (AUD) Segment by Company

Teva

Sun Pharmaceutical Industries

Merck KGaA

Mylan

Beijing Wellso Pharmaceutical Co

Zydus Pharmaceuticals

Taj Pharmaceuticals

TAGI Pharma Inc.

Rusan Pharma Ltd

Lundbeck

Glenmark Pharmaceuticals

Alvogen

Alkermes

Medications for Alcohol Use Disorder (AUD) Segment by Type

Acamprosate

Naltrexone

Disulfiram

Other

Medications for Alcohol Use Disorder (AUD) Segment by Application

Hospital

Rehabilitation Institutions

Others

Medications for Alcohol Use Disorder (AUD) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Medications for Alcohol Use Disorder (AUD) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Medications for Alcohol Use Disorder (AUD) key companies, revenue, market share, and recent developments.

3. To split the Medications for Alcohol Use Disorder (AUD) breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Medications for Alcohol Use Disorder (AUD) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Medications for Alcohol Use Disorder (AUD) significant trends, drivers, influence factors in global and regions.

6. To analyze Medications for Alcohol Use Disorder (AUD) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medications for Alcohol Use Disorder (AUD) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Medications for Alcohol Use Disorder (AUD) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medications for Alcohol Use Disorder (AUD).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Medications for Alcohol Use Disorder (AUD) industry.

Chapter 3: Detailed analysis of Medications for Alcohol Use Disorder (AUD) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Medications for Alcohol Use Disorder (AUD) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Medications for Alcohol Use Disorder (AUD) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Medications for Alcohol Use Disorder (AUD) Industry Trends Table 2. Medications for Alcohol Use Disorder (AUD) Industry Drivers Table 3. Medications for Alcohol Use Disorder (AUD) Industry Opportunities and Challenges Table 4. Medications for Alcohol Use Disorder (AUD) Industry Restraints Table 5. Global Medications for Alcohol Use Disorder (AUD) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Medications for Alcohol Use Disorder (AUD) Revenue Share by Company (2021-2026) Table 7. Global Medications for Alcohol Use Disorder (AUD) Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Medications for Alcohol Use Disorder (AUD) Key Company Manufacturing Base & Headquarters Table 9. Global Medications for Alcohol Use Disorder (AUD) Company, Product Type & Application Table 10. Global Medications for Alcohol Use Disorder (AUD) Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Medications for Alcohol Use Disorder (AUD) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Acamprosate Table 15. Significant Companies of Naltrexone Table 16. Significant Companies of Disulfiram Table 17. Significant Companies of Other Table 18. Global Medications for Alcohol Use Disorder (AUD) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Medications for Alcohol Use Disorder (AUD) Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Medications for Alcohol Use Disorder (AUD) Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type (2021-2026) Table 22. Global Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Table 24. Significant Companies of Rehabilitation Institutions Table 25. Significant Companies of Others Table 26. Global Medications for Alcohol Use Disorder (AUD) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Medications for Alcohol Use Disorder (AUD) Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Medications for Alcohol Use Disorder (AUD) Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application (2021-2026) Table 30. Global Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application (2027-2032) Table 31. Global Medications for Alcohol Use Disorder (AUD) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Medications for Alcohol Use Disorder (AUD) Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Medications for Alcohol Use Disorder (AUD) Sales Value Share by Region (2021-2026) Table 34. Global Medications for Alcohol Use Disorder (AUD) Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Medications for Alcohol Use Disorder (AUD) Sales Value Share by Region (2027-2032) Table 36. Global Medications for Alcohol Use Disorder (AUD) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Medications for Alcohol Use Disorder (AUD) Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Medications for Alcohol Use Disorder (AUD) Sales Value Market Share by Country (2021-2026) Table 39. Global Medications for Alcohol Use Disorder (AUD) Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Medications for Alcohol Use Disorder (AUD) Sales Value Market Share by Country (2027-2032) Table 41. Teva Company Information Table 42. Teva Business Overview Table 43. Teva Medications for Alcohol Use Disorder (AUD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Teva Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 45. Teva Recent Development Table 46. Sun Pharmaceutical Industries Company Information Table 47. Sun Pharmaceutical Industries Business Overview Table 48. Sun Pharmaceutical Industries Medications for Alcohol Use Disorder (AUD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Sun Pharmaceutical Industries Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 50. Sun Pharmaceutical Industries Recent Development Table 51. Merck KGaA Company Information Table 52. Merck KGaA Business Overview Table 53. Merck KGaA Medications for Alcohol Use Disorder (AUD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Merck KGaA Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 55. Merck KGaA Recent Development Table 56. Mylan Company Information Table 57. Mylan Business Overview Table 58. Mylan Medications for Alcohol Use Disorder (AUD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Mylan Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 60. Mylan Recent Development Table 61. Beijing Wellso Pharmaceutical Co Company Information Table 62. Beijing Wellso Pharmaceutical Co Business Overview Table 63. Beijing Wellso Pharmaceutical Co Medications for Alcohol Use Disorder (AUD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Beijing Wellso Pharmaceutical Co Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 65. Beijing Wellso Pharmaceutical Co Recent Development Table 66. Zydus Pharmaceuticals Company Information Table 67. Zydus Pharmaceuticals Business Overview Table 68. Zydus Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Zydus Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 70. Zydus Pharmaceuticals Recent Development Table 71. Taj Pharmaceuticals Company Information Table 72. Taj Pharmaceuticals Business Overview Table 73. Taj Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Taj Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 75. Taj Pharmaceuticals Recent Development Table 76. TAGI Pharma Inc. Company Information Table 77. TAGI Pharma Inc. Business Overview Table 78. TAGI Pharma Inc. Medications for Alcohol Use Disorder (AUD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. TAGI Pharma Inc. Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 80. TAGI Pharma Inc. Recent Development Table 81. Rusan Pharma Ltd Company Information Table 82. Rusan Pharma Ltd Business Overview Table 83. Rusan Pharma Ltd Medications for Alcohol Use Disorder (AUD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Rusan Pharma Ltd Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 85. Rusan Pharma Ltd Recent Development Table 86. Lundbeck Company Information Table 87. Lundbeck Business Overview Table 88. Lundbeck Medications for Alcohol Use Disorder (AUD) Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Lundbeck Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 90. Lundbeck Recent Development Table 91. Glenmark Pharmaceuticals Company Information Table 92. Glenmark Pharmaceuticals Business Overview Table 93. Glenmark Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Glenmark Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 95. Glenmark Pharmaceuticals Recent Development Table 96. Alvogen Company Information Table 97. Alvogen Business Overview Table 98. Alvogen Medications for Alcohol Use Disorder (AUD) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Alvogen Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 100. Alvogen Recent Development Table 101. Alkermes Company Information Table 102. Alkermes Business Overview Table 103. Alkermes Medications for Alcohol Use Disorder (AUD) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Alkermes Medications for Alcohol Use Disorder (AUD) Product Portfolio Table 105. Alkermes Recent Development Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Medications for Alcohol Use Disorder (AUD) Product Image Figure 2. Global Medications for Alcohol Use Disorder (AUD) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Medications for Alcohol Use Disorder (AUD) Market Size (2021-2032) & (US$ Million) Figure 4. Global Medications for Alcohol Use Disorder (AUD) Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Acamprosate Image Figure 8. Naltrexone Image Figure 9. Disulfiram Image Figure 10. Other Image Figure 11. Global Medications for Alcohol Use Disorder (AUD) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Medications for Alcohol Use Disorder (AUD) Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type (2021-2032) Figure 14. Hospital Image Figure 15. Rehabilitation Institutions Image Figure 16. Others Image Figure 17. Global Medications for Alcohol Use Disorder (AUD) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Medications for Alcohol Use Disorder (AUD) Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application (2021-2032) Figure 20. Global Medications for Alcohol Use Disorder (AUD) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Medications for Alcohol Use Disorder (AUD) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Medications for Alcohol Use Disorder (AUD) Sales Value (2021-2032) & (US$ Million) Figure 23. North America Medications for Alcohol Use Disorder (AUD) Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Medications for Alcohol Use Disorder (AUD) Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Medications for Alcohol Use Disorder (AUD) Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Medications for Alcohol Use Disorder (AUD) Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Medications for Alcohol Use Disorder (AUD) Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Medications for Alcohol Use Disorder (AUD) Sales Value (2021-2032) & (US$ Million) Figure 29. South America Medications for Alcohol Use Disorder (AUD) Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Medications for Alcohol Use Disorder (AUD) Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Medications for Alcohol Use Disorder (AUD) Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Acamprosate
  • Naltrexone
  • Disulfiram
  • Other
Applications
  • Hospital
  • Rehabilitation Institutions
  • Others
Companies covered
  • Teva
  • Sun Pharmaceutical Industries
  • Merck KGaA
  • Mylan
  • Beijing Wellso Pharmaceutical Co
  • Zydus Pharmaceuticals
  • Taj Pharmaceuticals
  • TAGI Pharma Inc.
  • Rusan Pharma Ltd
  • Lundbeck
  • Glenmark Pharmaceuticals
  • Alvogen
  • Alkermes

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Medications for Alcohol Use Disorder (AUD) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Medications for Alcohol Use Disorder (AUD) Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Medications for Alcohol Use Disorder (AUD) Market Dynamics
  1. 2.1 Medications for Alcohol Use Disorder (AUD) Industry Trends
  2. 2.2 Medications for Alcohol Use Disorder (AUD) Industry Drivers
  3. 2.3 Medications for Alcohol Use Disorder (AUD) Industry Opportunities and Challenges
  4. 2.4 Medications for Alcohol Use Disorder (AUD) Industry Restraints
3 Medications for Alcohol Use Disorder (AUD) Market by Company
  1. 3.1 Global Medications for Alcohol Use Disorder (AUD) Company Revenue Ranking in 2025
  2. 3.2 Global Medications for Alcohol Use Disorder (AUD) Revenue by Company (2021-2026)
  3. 3.3 Global Medications for Alcohol Use Disorder (AUD) Company Ranking (2024-2026)
  4. 3.4 Global Medications for Alcohol Use Disorder (AUD) Company Manufacturing Base and Headquarters
  5. 3.5 Global Medications for Alcohol Use Disorder (AUD) Company Product Type and Application
  6. 3.6 Global Medications for Alcohol Use Disorder (AUD) Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Medications for Alcohol Use Disorder (AUD) Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Medications for Alcohol Use Disorder (AUD) Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Medications for Alcohol Use Disorder (AUD) Market by Type
  1. 4.1 Medications for Alcohol Use Disorder (AUD) Type Introduction
  2. 4.1.1 Acamprosate
  3. 4.1.2 Naltrexone
  4. 4.1.3 Disulfiram
  5. 4.1.4 Other
  6. 4.2 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Type
  7. 4.2.1 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Type (2021-2032)
  9. 4.2.3 Global Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type (2021-2032)
5 Medications for Alcohol Use Disorder (AUD) Market by Application
  1. 5.1 Medications for Alcohol Use Disorder (AUD) Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Rehabilitation Institutions
  4. 5.1.3 Others
  5. 5.2 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Application
  6. 5.2.1 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Application (2021-2032)
  8. 5.2.3 Global Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application (2021-2032)
6 Medications for Alcohol Use Disorder (AUD) Regional Value Analysis
  1. 6.1 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Region (2021-2032)
  3. 6.2.1 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Region: 2021-2026
  4. 6.2.2 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Medications for Alcohol Use Disorder (AUD) Sales Value (2021-2032)
  7. 6.3.2 North America Medications for Alcohol Use Disorder (AUD) Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Medications for Alcohol Use Disorder (AUD) Sales Value (2021-2032)
  10. 6.4.2 Europe Medications for Alcohol Use Disorder (AUD) Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Medications for Alcohol Use Disorder (AUD) Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Medications for Alcohol Use Disorder (AUD) Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Medications for Alcohol Use Disorder (AUD) Sales Value (2021-2032)
  16. 6.6.2 South America Medications for Alcohol Use Disorder (AUD) Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Medications for Alcohol Use Disorder (AUD) Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Medications for Alcohol Use Disorder (AUD) Sales Value Share by Country, 2025 VS 2032
7 Medications for Alcohol Use Disorder (AUD) Country-level Value Analysis
  1. 7.1 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Country (2021-2032)
  3. 7.2.1 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Country (2021-2026)
  4. 7.2.2 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Medications for Alcohol Use Disorder (AUD) Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Sun Pharmaceutical Industries
  8. 8.2.1 Sun Pharmaceutical Industries Company Information
  9. 8.2.2 Sun Pharmaceutical Industries Business Overview
  10. 8.2.3 Sun Pharmaceutical Industries Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sun Pharmaceutical Industries Medications for Alcohol Use Disorder (AUD) Product Portfolio
  12. 8.2.5 Sun Pharmaceutical Industries Recent Developments
  13. 8.3 Merck KGaA
  14. 8.3.1 Merck KGaA Company Information
  15. 8.3.2 Merck KGaA Business Overview
  16. 8.3.3 Merck KGaA Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck KGaA Medications for Alcohol Use Disorder (AUD) Product Portfolio
  18. 8.3.5 Merck KGaA Recent Developments
  19. 8.4 Mylan
  20. 8.4.1 Mylan Company Information
  21. 8.4.2 Mylan Business Overview
  22. 8.4.3 Mylan Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mylan Medications for Alcohol Use Disorder (AUD) Product Portfolio
  24. 8.4.5 Mylan Recent Developments
  25. 8.5 Beijing Wellso Pharmaceutical Co
  26. 8.5.1 Beijing Wellso Pharmaceutical Co Company Information
  27. 8.5.2 Beijing Wellso Pharmaceutical Co Business Overview
  28. 8.5.3 Beijing Wellso Pharmaceutical Co Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Beijing Wellso Pharmaceutical Co Medications for Alcohol Use Disorder (AUD) Product Portfolio
  30. 8.5.5 Beijing Wellso Pharmaceutical Co Recent Developments
  31. 8.6 Zydus Pharmaceuticals
  32. 8.6.1 Zydus Pharmaceuticals Company Information
  33. 8.6.2 Zydus Pharmaceuticals Business Overview
  34. 8.6.3 Zydus Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Zydus Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Product Portfolio
  36. 8.6.5 Zydus Pharmaceuticals Recent Developments
  37. 8.7 Taj Pharmaceuticals
  38. 8.7.1 Taj Pharmaceuticals Company Information
  39. 8.7.2 Taj Pharmaceuticals Business Overview
  40. 8.7.3 Taj Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Taj Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Product Portfolio
  42. 8.7.5 Taj Pharmaceuticals Recent Developments
  43. 8.8 TAGI Pharma Inc.
  44. 8.8.1 TAGI Pharma Inc. Company Information
  45. 8.8.2 TAGI Pharma Inc. Business Overview
  46. 8.8.3 TAGI Pharma Inc. Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  47. 8.8.4 TAGI Pharma Inc. Medications for Alcohol Use Disorder (AUD) Product Portfolio
  48. 8.8.5 TAGI Pharma Inc. Recent Developments
  49. 8.9 Rusan Pharma Ltd
  50. 8.9.1 Rusan Pharma Ltd Company Information
  51. 8.9.2 Rusan Pharma Ltd Business Overview
  52. 8.9.3 Rusan Pharma Ltd Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Rusan Pharma Ltd Medications for Alcohol Use Disorder (AUD) Product Portfolio
  54. 8.9.5 Rusan Pharma Ltd Recent Developments
  55. 8.10 Lundbeck
  56. 8.10.1 Lundbeck Company Information
  57. 8.10.2 Lundbeck Business Overview
  58. 8.10.3 Lundbeck Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Lundbeck Medications for Alcohol Use Disorder (AUD) Product Portfolio
  60. 8.10.5 Lundbeck Recent Developments
  61. 8.11 Glenmark Pharmaceuticals
  62. 8.11.1 Glenmark Pharmaceuticals Company Information
  63. 8.11.2 Glenmark Pharmaceuticals Business Overview
  64. 8.11.3 Glenmark Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Glenmark Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Product Portfolio
  66. 8.11.5 Glenmark Pharmaceuticals Recent Developments
  67. 8.12 Alvogen
  68. 8.12.1 Alvogen Company Information
  69. 8.12.2 Alvogen Business Overview
  70. 8.12.3 Alvogen Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Alvogen Medications for Alcohol Use Disorder (AUD) Product Portfolio
  72. 8.12.5 Alvogen Recent Developments
  73. 8.13 Alkermes
  74. 8.13.1 Alkermes Company Information
  75. 8.13.2 Alkermes Business Overview
  76. 8.13.3 Alkermes Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Alkermes Medications for Alcohol Use Disorder (AUD) Product Portfolio
  78. 8.13.5 Alkermes Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst